Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life by Akbaba, Sati et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Percutaneous parametrial dose escalation in women with advanced cervical
cancer: feasibility and efficacy in relation to long-term quality of life
Akbaba, Sati; Oelmann-Avendano, Jan Tobias; Bostel, Tilman; Rief, Harald; Nicolay, Nils Henrik;
Debus, Juergen; Lindel, Katja; Foerster, Robert
Abstract: Background We analyzed long-term quality of life (QoL) and prognostic factors for QoL as well
as clinical outcome in patients with advanced cervical cancer (ACC) treated with primary radiochemother-
apy (RChT) consisting of external beam radiotherapy (EBRT) with or without sequential or simultaneous
integrated boost (SIB) to the parametria, intracavitary brachytherapy and concomitant chemotherapy
(ChT). Patients and methods Eighty-three women were treated with primary RChT between 2008 and
2014. Survival of all patients was calculated and prognostic factors for survival were assessed in univariate
and multivariate analysis. In 31 patients QoL was assessed in median 3 years (range 2-8 years) after treat-
ment. QoL was compared to published normative data and the influence of age, tumour stage, treatment
and observed acute toxicities was analyzed. Results Thirty-six patients (43.4%) died, 18 (21.7%) had a
local recurrence and 24 (28.9%) had a distant progression. Parametrial boost (p = 0.027) and ChT (p
= 0.041) were independent prognostic factors for overall survival in multivariate analysis. Specifically, a
parametrial equivalent doses in 2-Gy fractions (EQD2) > 50 Gy was associated with an improved overall
survival (OS) (p = 0.020), but an EQD2 > 53 Gy did not further improve OS (p = 0.194). Tumour
size was the only independent prognostic factor for local control (p = 0.034). Lymph node status (p =
0.038) and distant metastases other than in paraaortic lymph nodes (p = 0.002) were independent prog-
nostic factors for distant progressionfree survival. QoL was generally inferior to the reference population.
Age only correlated with menopausal symptoms (p = 0.003). The degree of acute gastrointestinal (p =
0.038) and genitourinary (p = 0.041) toxicities correlated with the extent of chronic symptom experience.
Sexual/vaginal functioning was reduced in patients with larger tumours (p = 0.012). Parametrial EQD2
> 53 Gy correlated with reduced sexual/vaginal functioning (p = 0.009) and increased sexual worry (p
= 0.009). Whether parametrial dose escalation was achieved by sequential boost or SIB, did not affect
survival or QoL. Conclusions Primary RChT is an effective treatment, but long-term QoL is reduced.
The degree of acute side effects of RChT correlates with the extent of chronic symptoms. Patients benefit
from parametrial SIB or sequential boost, but an EQD2 > 53 Gy does not further improve survival and
negatively affects QoL.
DOI: https://doi.org/10.2478/raon-2018-0029
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-167785
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Akbaba, Sati; Oelmann-Avendano, Jan Tobias; Bostel, Tilman; Rief, Harald; Nicolay, Nils Henrik; Debus,
Juergen; Lindel, Katja; Foerster, Robert (2018). Percutaneous parametrial dose escalation in women with
advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life. Radiology and
Oncology, 52(3):320-328.
DOI: https://doi.org/10.2478/raon-2018-0029
2
Radiol Oncol 2018; 52(3): 320-328. doi: 10.2478/raon-2018-0029
320
research article
Percutaneous parametrial dose escalation 
in women with advanced cervical cancer: 
feasibility and efficacy in relation to long-term 
quality of life
Sati Akbaba1,2, Jan Tobias Oelmann-Avendano1,2, Tilman Bostel1,2, Harald Rief1,2,3, 
Nils Henrik Nicolay1,2,4,5, Juergen Debus1,2,4, Katja Lindel1,2,6, Robert Foerster1,2,7
1  Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
2  National Center for Radiation Research in Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), 
Heidelberg, Germany
3  Gemeinschaftspraxis Strahlentherapie Bonn-Rhein-Sieg, Bonn, Germany
4  Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
5  Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany
6  Department of Radiation Oncology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
7  Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland
Radiol Oncol 2018; 52(3): 320-328.
Received 14 February 2018
Accepted 09 May 2018
Correspondence to: Robert Foerster, M.D., Department of Radiation Oncology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, 
Switzerland. Phone: +41 44 255 9959; Fax: +41 44 255 4547; E-mail: robert.foerster@usz.ch
Disclosure: No potential conflict of interest were disclosed.
Background. We analyzed long-term quality of life (QoL) and prognostic factors for QoL as well as clinical outcome 
in patients with advanced cervical cancer (ACC) treated with primary radiochemotherapy (RChT) consisting of ex-
ternal beam radiotherapy (EBRT) with or without sequential or simultaneous integrated boost (SIB) to the parametria, 
intracavitary brachytherapy and concomitant chemotherapy (ChT).
Patients and methods. Eighty-three women were treated with primary RChT between 2008 and 2014. Survival of 
all patients was calculated and prognostic factors for survival were assessed in univariate and multivariate analysis. In 
31 patients QoL was assessed in median 3 years (range 2–8 years) after treatment. QoL was compared to published 
normative data and the influence of age, tumour stage, treatment and observed acute toxicities was analyzed. 
Results. Thirty-six patients (43.4%) died, 18 (21.7%) had a local recurrence and 24 (28.9%) had a distant progression. 
Parametrial boost (p = 0.027) and ChT (p = 0.041) were independent prognostic factors for overall survival in multivari-
ate analysis. Specifically, a parametrial equivalent doses in 2-Gy fractions (EQD2) > 50 Gy was associated with an 
improved overall survival (OS) (p = 0.020), but an EQD2 > 53 Gy did not further improve OS (p = 0.194). Tumour size was 
the only independent prognostic factor for local control (p = 0.034). Lymph node status (p = 0.038) and distant metas-
tases other than in paraaortic lymph nodes (p = 0.002) were independent prognostic factors for distant progression-
free survival. QoL was generally inferior to the reference population. Age only correlated with menopausal symptoms 
(p = 0.003). The degree of acute gastrointestinal (p = 0.038) and genitourinary (p = 0.041) toxicities correlated with 
the extent of chronic symptom experience. Sexual/vaginal functioning was reduced in patients with larger tumours 
(p = 0.012). Parametrial EQD2 > 53 Gy correlated with reduced sexual/vaginal functioning (p = 0.009) and increased 
sexual worry (p = 0.009). Whether parametrial dose escalation was achieved by sequential boost or SIB, did not affect 
survival or QoL.
Conclusions. Primary RChT is an effective treatment, but long-term QoL is reduced. The degree of acute side effects 
of RChT correlates with the extent of chronic symptoms. Patients benefit from parametrial SIB or sequential boost, but 
an EQD2 > 53 Gy does not further improve survival and negatively affects QoL.
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Introduction
Primary radiochemotherapy (RChT) with external 
beam radiotherapy (EBRT), intracavitary brachy-
therapy (ICBT), and concomitant chemotherapy 
(ChT) remains a frequently used treatment for 
advanced cervical cancer (ACC). However, local 
tumour control requires comparatively large dos-
es, which in turn may lead to relevant treatment-
related morbidity.1,2 In recent years, image guided 
adaptive brachytherapy (IGABT), based on mag-
netic resonance imaging (MRI) and combined in-
terstitial / intracavitary brachytherapy (IBT/ICBT), 
has been successfully implemented as the new 
standard of care for local dose escalation and sub-
stantial reduction of therapy-related morbidity.3-5
However, access to IGABT is limited at many 
brachytherapy facilities. Therefore, despite evi-
dence of the inferiority of percutaneous boosting in 
terms of organ sparing and target coverage, anoth-
er approach has been to combine ICBT with mod-
ern radiotherapy (RT) techniques, such as intensi-
ty-modulated radiotherapy (IMRT) with simulta-
neous integrated boost (SIB) to the parametria, for 
percutaneous local dose escalation.6,7 There is a low 
incidence of acute toxicities after SIB, but clinical 
outcome and QoL of these patients have not been 
investigated so far.7 Due to limited access to IGABT 
at many brachytherapy facilities and the unknown 
effects of SIB in terms of chronic morbidity, IMRT 
with sequential boost remains a widely used meth-
od for parametrial dose escalation. Given the com-
paratively young age of patients with cervical can-
cer and improving prognosis, long-term quality of 
life (QoL) and extent of chronic morbidity become 
increasingly important issues.
Therefore, we conducted this study to analyze 
feasibility and efficacy of a percutaneous parame-
trial boost in relation to long-term QoL as well as 
to assess tumour- and treatment-related prognostic 
factors for long-term QoL and outcome in women 
with ACC.
Patients and methods
Between 2008 and 2014, eighty-three women with 
ACC underwent primary treatment at our depart-
ment. Patients’ data were acquired from the institu-
tional electronic patient charts and the institutional 
follow-up database. Median age at first diagnosis 
was 57 years (range 32–90 years; Table 1). Due to 
the substantially differing fractionation schedules, 
all reported doses were recalculated as equivalent 
doses in 2-Gy fractions with α/β = 10 (EQD210) for 
the tumour and α/β = 3 (EQD23) for the organs at 
risk (OARs). OAR doses were documented for vol-
umes of 0.1 cm3 (D0.1cc), 1 cm3 (D1cc) and 2 cm3 
(D2cc). They were calculated as the sum of the indi-
vidual doses received from all brachytherapy frac-
tions and the EBRT plan.8 
Survival was plotted according to Kaplan and 
Meier. Overall survival (OS) was defined as the 
time between first diagnosis and death. Local pro-
gression-free survival (LPFS) was defined as the 
time between first diagnosis and occurrence of any 
local progression. Since patients with distant me-
tastases (cM1a and cM1c) at first diagnosis were in-
TABLE 1. Patients’ characteristics
Age
   Median 57 years
   Range 32–90 years
n %
Histology
   Squamous cell carcinoma 67 80.7%
   Adenocarcinoma 14 16.9%
   Adenosquamous carcinoma 2 2.4%
Grading  
   G1 8 9.6%
   G2 24 28.9%
   G3 35 42.2%
   GX 16 19.3%
FIGO stage  
    I 2 2.4%
   II 40 48.2%
   III 15 18.1%
   IV 26 31.3%
Tumour size  
   T1 3 3.6%
   T2 46 55.4%
   T3 25 30.1%
   T4 9 10.8%
Lymph node status  
   N0 28 33.7%
   N1 55 66.3%
Distant metastases  
   M0 64 77.1%
   M1a 12 14.5%
   M1c 7 8.4%
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cluded in this study, distant progression-free sur-
vival (DPFS) was defined as the interval between 
first diagnosis of cervical cancer and occurrence 
of new distant metastases. Prognostic factors for 
survival were analyzed with the log-rank test (uni-
variate analysis) and a Cox proportional hazards 
model (multivariate analysis).
Three years (median; range 2–8 years) af-
ter treatment, patients were approached during 
clinical follow-up examinations and asked to fill-
in the European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life 
Questionnaire for Cancer Patients 30 (QLQ-C30) 
and the Cervical Cancer Module (QLQ-CX24). 
Thirty-one women agreed to participate. The dif-
ference between patients’ QoL items scores and 
published German reference values was analyzed 
with the t-test (9). Possible prognostic factors for 
QoL (age, stage, tumour size, lymph node status, 
distant metastases status, histological grading, 
histology, RT techniques, applied RT doses, OAR 
doses, ChT, treatment duration, observed acute 
toxicities, anemia during RChT, number of trans-
fusions during RChT) were investigated with an 
analysis of variances and the t-test. Age was used 
as a covariate. A p-value ≤ 0.05 was considered sta-
tistically significant. All statistical analyses were 
performed with IBM SPSS version 24.0.
This study was conducted in accordance with 
the declaration of Helsinki and was approved by 
the responsible independent ethics committee on 
22 October 2012 (#S-513/2012). The requirement of 
informed consent was waived by the ethics com-
mittee, due to the retrospective nature of the study.
Results
Treatment and dose-volume histogram 
analysis
RT was conducted as EBRT (69.9% IMRT, 30.1% 
3D-conformal RT), with or without sequential 
boost / SIB to parametria and involved pelvic / 
paraaortic lymph nodes (43.4% no boost, 37.3% 
sequential boost, 19.3% SIB), and high-dose-rate 
(HDR) ICBT boost (tandem and ring applicator). 
Median EBRT EQD210 to the whole pelvic (and par-
aaortic) planning target volume (PTV) was 44 Gy 
(range 35–51 Gy) and median parametrial EQD210 
was 53 Gy (range 38–67 Gy). Including ICBT boost, 
as prescribed to point A, with a median EQD210 
of 40 Gy (range 10–50 Gy), the median prescribed 
primary tumour EQD210 was 84 Gy (range 54–95 
Gy). Seventy-one patients (85.5%) received con-
TABLE 2. Treatment and toxicity
Radiotherapy dose in EQD2 (/ = 10)
Median EBRT 44 Gy
Range EBRT 35–51 Gy
Median parametria 53 Gy
Range parametria 38–67 Gy
Median HDR-BT 40 Gy
Range HDR-BT 10–50 Gy
n %
Radiotherapy technique  
   IMRT 58 69.9%
   3D-conformal 25 30.1%
Parametrial boost
   No boost 36 43.4%
   Sequential 31 37.3%
   SIB 16 19.3%
Parametrial dose in EQD2 ( = 10)
   ≤ 53 Gy 56 67.5%
   > 53 Gy 27 32.5%
Simultanous chemotherapy  
   Cisplatin 40 mg/m² 71 85.5%
   None 12 14.5%
Total treatment duration  
   < 6 weeks 9 10.8%
   6-8 weeks 52 62.7%
   ≥ 9 weeks 22 26.5%
Anemia during therapy  
   min. Hb < 10 g/dl 38 45.8%
   min. Hb ≥ 10 g/dl 45 54.2%
Transfusions   
   ≤ 2 ECs 69 83.1%
   > 2 ECs 14 16.9%
Observed acute GI toxicity  
   Grade 0 33 39.8%
   Grade I 15 18.1%
   Grade II 20 24.1%
   Grade III 12 14.5%
   Grade IV 3 3.6%
Observed acute GU toxicity  
   Grade 0 15 18.1%
   Grade I 34 41.0%
   Grade II 28 33.7%
   Grade III 6 7.2%
EBRT = external beam radiotherapy; ECs = erythrocyte concentrates; EQD2 = equivalent doses in 
2-Gy fractions; GI = gastrointestinal; GU = genitourinary; Hb = haemoglobin; HDR-BT = high-dose-
rate brachytherapy; IMRT = intensity-modulated radiotherapy; SIB = simultaneous integrated boost 
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tic factor for LPFS (T3/4 vs. T1/2, HR 2.668 [95%CI 
1.032–6.896], p = 0.043). Regarding freedom from 
distant progression (DPFS), presence of pel-
vic lymph node metastases (N1 vs. N0, HR 4.383 
[95%CI 1.003–19.154], p = 0.05) as well as distant 
metastases other than in the paraaortic lymph 
nodes at initial diagnosis (M1c vs. M0/M1a, HR 
4.646 [95%CI 1.466–14.719], p = 0.009) were inde-
pendent prognostic factors.
Quality of life analysis
We found the values of the functioning and symp-
toms scores in our cohort to be significantly worse 
comparison those from the normative population 
(Table 4). Generally, age must be considered when 
looking at quality of life and we used age as a co-
variate for our analyses, however age only corre-
lated with menopausal symptoms (p = 0.003) in 
our analysis and did not affect global health status 
or any of the other functioning or symptom items 
scores from the QLQ-C30 or QLQ-CX24 question-
naires in our cohort. 
The doses to bladder, sigmoid and rectum did 
not correlate with any of the QoL item scores. 
However, we found a statistically significant cor-
relation between the degree of observed acute 
gastrointestinal (GI) and genitourinary (GU) tox-
icities with chronic symptom experience (p = 0.038 
and p = 0.041), which can be considered an indi-
cator for the known dose-volume dependence of 
FIGURE 1. Overall survival dependent on parametrial equivalent dose in 2-Gy 
fractions (EQD2) with α/β = 10.
comitant ChT with 4–6 cycles of cisplatin 40 mg/
m2 weekly (Table 2).
Mean bladder D0.1cc, D1cc and D2cc were 130.2 
Gy (± SD 31.7 Gy), 105.6 Gy (± SD 14.2 Gy) and 
97.1 Gy (± SD 9.9 Gy), respectively. Mean sigmoid 
D0.1cc, D1cc and D2cc were 71.9 Gy (± SD 10.6 Gy), 
64.1 Gy (± SD 7.9 Gy) and 61.1 Gy (± SD 6.9 Gy), 
respectively. Mean rectum D0.1cc, D1cc and D2cc 
were 89.8 Gy (± SD 23.1 Gy), 74.3 Gy (± SD 12.8 Gy) 
and 68.8 Gy (± SD 9.4 Gy), respectively.
Survival analysis
Thirty-six patients (43.4%) died, 18 (21.7%) had a 
local progression and 24 (28.9%) developed new 
distant metastases during follow-up. Calculated 
3- / 5-year LPFS, DPFS and OS were 80.5% / 73.2%, 
76.7% / 65.3% and 66.5% / 53.2%, respectively.
In univariate analysis (Table 3), Fédération 
Internationale de Gynécologie et d’Obstétrique 
(FIGO) stage (I/II vs. III/IV; p = 0.015), tumour size 
(T1/2 vs. T3/4; p = 0.036), parametrial boost (yes vs. 
no; p = 0.037), parametrial dose (EQD210 ≤ 50 Gy vs. 
> 50 Gy; p = 0.020 and EQD210 < 53 Gy vs. 53 Gy vs. 
> 53 Gy; p = 0.017), simultaneous ChT (yes vs. no; p 
= 0.004), total treatment duration (6–8 weeks vs. ≥ 9 
weeks; p = 0.027), anemia during therapy (minimal 
hemoglobin < 10 g/dl vs. ≥ 10 g/dl; p = 0.039) and 
number of erythrocyte concentrate transfusions (≤ 
2 vs. > 2; p = 0.007) were prognostic factors for OS. 
Histological grading showed a tendency towards 
statistical significance (G1/2 vs. G3; p = 0.053). 
Importantly, a percutaneous dose escalation in 
the parametria beyond an EQD210 of 53 Gy did not 
further improve survival (p = 0.194; Figure 1). For 
DPFS, only tumour size (T1/2 vs. T3/4; p = 0.034) 
was a prognostic factor. Lower FIGO stage (FIGO I/
II vs. III/IV; p = 0.072) and conductance of a parame-
trial boost (yes vs. no; p = 0.095) showed a tendency 
towards improved LPFS. DPFS was prolonged in 
patients without lymph node metastases (N0 vs. 
N1; p = 0.038) and in patients without distant me-
tastases other than in paraaortic lymph nodes (M0/
M1a vs. M1c; p = 0.002) as well as in patients with 
low or intermediate histological grading (G1/2 vs. 
G3; p = 0.037). In none of three endpoints we found 
any difference in outcome between patients receiv-
ing SIB or sequential boost.
In multivariate analysis (Table 3), parametrial 
boost (yes vs. no, HR 0.417 [95%CI 0.192–0.900], 
p = 0.027) and simultaneous ChT (yes vs. no, HR 
0.382 [95%CI 0.152–0.961], p = 0.041) remained as 
independent prognostic factors for OS. Advanced 
tumour size was the only independent prognos-
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chronic morbidity. Patients with higher degree of 
observed acute GI toxicity also complained more 
about chronic diarrhea (p = 0.053). Since most of 
our patients underwent IMRT and all of them re-
ceived HDR ICBT, we found no difference in QoL 
between RT techniques. Importantly, we could 
show, that a parametrial EQD210 > 53 Gy statisti-
cally significantly correlated with reduced sexual/
vaginal functioning (p = 0.009) and increased sex-
ual worry (p = 0.009). Additionally, these patients 
also suffered more from chronic constipation (p = 
TABLE 3. Prognostic factors for survival
OS
Univariate analysis (log-rank test)
Mean 
(months) p-value
FIGO stage  
   FIGO I/II 72.6 0.015
   FIGO III/IV 50.8  
Tumour size  
   T1/2 69.2 0.036
   T3/4 50.4  
Grading  
   G1/2 72.4 0.053
   G3 50.5  
Parametrial boost  
   yes 69.9 0.037
   no 51.2  
Parametrial dose in EQD2 (= 10)  
   ≤ 50 Gy 50.7 0.020
   > 50 Gy 71.5  
   ≤ 53 Gy 59.5 0.194
   > 53 Gy 64.1  
Chemotherapy  
   yes 67.4 0.004
   no 32.1  
Total treatment duration  
   6–8 weeks 71.6 0.027
   ≥ 9 weeks 44.7  
Anemia during therapy  
   min. Hb < 10 g/dl 52.1 0.039
   min. Hb ≥ 10 g/dl 70.3  
Transfusions  
   ≤ 2 ECs 67.6 0.007
   > 2 ECs 41.6   
LPFS Mean (months) p-value
FIGO stage  
   FIGO I/II 85.9 0.072
   FIGO III/IV 66.7  
Tumour size  
   T1/2 85.7 0.034
   T3/4 64.1  
Parametrial boost  
   yes 84.1 0.095
   no 56.1  
DPFS Mean (months) p-value
Lymph node status  
   N0 85.6 0.038
   N1 61.0  
Distant metastases  
   M0/M1a 75.2 0.002
   M1c 37.1  
Grading  
   G1/2 84.6 0.037
   G3 59.8   
Multivariate analysis (Cox regression)
OS HR 95% CI p-value
Parametrial boost  
   yes 0.417 0.192-0.900 0.027
   no Reference  
Chemotherapy  
   yes 0.382 0.152-0.961 0.041
   no Reference  
LPFS HR 95% CI p-value
Tumour size  
   T1/2 Reference  
   T3/4 2.668 1.032-6.896 0.043
DPFS HR 95% CI p-value
Lymph node status  
   N0 Reference  
   N1 4.383 1.003-19.154 0.05
Distant metastases  
   M0/M1a Reference  
   M1c 4.646 1.466-14.719 0.009
DPFS = Distant progression-free survival; ECs = erythrocyte concentrates; 
EQD2 = equivalent doses in 2-Gy fractions; FIGO = Fédération 
Internationale de Gynécologie et d’Obstétrique; Hb = haemoglobin; LPFS 
= Local progression-free survival OS = overall survival 
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0.057). Whether parametrial dose escalation was 
achieved by sequential boost or SIB did not affect 
QoL. Sexual/vaginal functioning was statistically 
significantly worse in patients with T3/4 tumours 
compared to those with T1/2 tumours (p = 0.012). 
Details are shown in Table 5.
Discussion
The objective of this study was to analyze the feasi-
bility and efficacy of a parametrial boost in relation 
to long-term QoL of patients with ACC. Secondly, 
we aimed to assess tumour- and treatment-related 
prognostic factors for long-term QoL and clinical 
outcome.
Currently, for the QLQ-CX24 items, there are 
only reference populations from 2 Korean studies 
available and possible social or cultural differences 
prevent these cohorts from being reference popula-
tions for European studies.10,11 Therefore, we were 
unable to compare the QLQ-CX24 items scores of 
our patients and we can only report on the com-
parison between our patients’ QLQ-C30 items 
scores and German normative data.9 Compared to 
the reference population, the patients in our cohort 
had significantly worse functioning and symptoms 
item scores. Similar results have been reported in 
a large population-based study from the United 
States. They found health-related QoL in survivors 
of cervical cancer to be worse than in the normal 
population as well.12 In women treated with IGABT 
within the “European and international study on 
MRI-guided brachytherapy in locally advanced 
cervical cancer” (EMBRACE), after a median fol-
low-up of 21 months, functioning and general QoL 
returned to levels of the reference population, but 
several clearly treatment-related symptoms, e.g. 
diarrhea and sexual dysfunction, did develop or 
persist in those patients during follow-up as well.13 
While we, probably due to the small cohort, 
were unable to show a significant correlation be-
tween the doses received by the OARs and any of 
the QoL item scores, others have found a significant 
dose-volume effect relationship for late rectal and 
urinary morbidity. Particularly, patients with blad-
der D2cc > 95 Gy and rectum D2cc ≥ 75 Gy are at 
risk for severe late toxicities.14,15 It has been shown 
that chronic bladder and rectal morbidity can be 
further reduced by IGABT.3 Therefore, in the on-
going EMBRACE-2 trial, the planning aims / limits 
for the prescribed EQD23 to rectum (D2cc < 65 / < 75 
Gy) and bladder (D2cc < 80 / < 90 Gy) are substan-
tially lower than the mean dose values achieved in 
TABLE 4. Quality of life of patients compared to reference populations (EORTC 
QLQ-C30)
n mean SD p-value
Global health status  
   Reference 1309 74.5 15.5 0.001
   Patients 30 60.3 21.7  
Physical functioning  
   Reference 1309 91.5 15.5 < 0.001
   Patients 30 73.6 19.6  
Role functioning    
   Reference 1309 89.9 20.6 < 0.001
   Patients 31 58.1 33.0  
Emotional functioning  
   Reference 1309 83.2 19.3 0.001
   Patients 31 65.1 26.7  
Cognitive functioning    
   Reference 1309 93.4 14.6 < 0.001
   Patients 31 73.2 28.4  
Social functioning  
   Reference 1309 93.3 17.1 < 0.001
   Patients 31 69.9 29.0  
Fatigue     
   Reference 1309 16.4 21.4 < 0.001
   Patients 31 51.6 28.0  
Nausea / Vomiting  
   Reference 1309 2.4 9.6 0.030
   Patients 31 11.3 21.7  
Pain     
   Reference 1309 17.0 24.2 0.025
   Patients 31 26.9 24.2  
Dyspnea  
   Reference 1309 7.2 18.7 0.020
   Patients 30 18.9 25.8  
Insomnia     
   Reference 1309 13.0 23.6 < 0.001
   Patients 31 40.9 36.2  
Appetite loss  
   Reference 1309 4.2 13.9 0.002
   Patients 31 21.5 27.7  
Constipation    
   Reference 1309 3.1 12.1 < 0.001
   Patients 31 22.6 27.7  
Diarrhea  
   Reference 1309 2.9 12.7 < 0.001
   Patients 31 29.0 30.7  
Financial difficulties    
   Reference 1309 4.8 16.3 < 0.001
   Patients 31 29.0 29.5  
EORTC = European Organization for Research and Treatment of Cancer; QLQ-C30 = quality of life 
questionnaire for cancer patients 30
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our cohort.5  Consequently, the QLQ-CX24 symp-
tom experience score was higher in our patients 
compared to those treated within the EMBRACE 
study (18.1 ± SD 16.4 vs. 12.1 ± SD 11.9; p = 0.063) af-
ter 36 months of follow-up.13 As a further indicator 
for the dose-volume dependence of chronic mor-
bidity, we found the degree of RT-related acute 
GI und GU toxicities in patients with ACC to sta-
tistically significantly correlate with the extent of 
chronic symptoms and we have already shown this 
correlation in a previous study from our institution 
on women with endometrial cancer.16 In that study 
TABLE 5. Prognostic factors for patients’ long-term quality of life (EORTC QLQ-C30, 
QLQ-CX24)
 n mean SD p-value
Diarrhea
   Acute GI 0 11 12.1 16.8 0.053
   Acute GI I/II 15 35.6 32.0  
   Acute GI III/IV 5 46.7 38.0  
Constipation
   Parametria ≤ 53 Gy* 19 14.0 23.1 0.057
   Parametria > 53 Gy* 11 33.3 29.8  
Symptom experience
   Acute GI toxicity 0 11 9.4 8.6 0.038
   Acute GI toxicity I/II 14 20.6 15.9  
   Acute GI toxicity III/IV 5 30.3 22.7  
   Acute GU toxicity 0 5 14.3 12.9 0.041
   Acute GU toxicity I/II 22 22.4 9.7  
   Acute GU toxicity III/IV 3 38.4 33.5  
Menopausal symptoms
   ≤ 49 years 7 57.1 25.2 0.033
   50–59 years 12 36.1 36.1  
   60–69 years 7 14.3 26.2  
   ≥ 70 years 4 8.3 16.7  
Sexual / vaginal functioning
   T1/2 9 93.5 11.6 0.012
   T3/4 3 41.7 52.0  
   Parametria ≤ 53 Gy* 8 96.9 6.2 0.009
   Parametria > 53 Gy* 4 47.9 44.2  
Sexual worry  
   Parametria ≤ 53 Gy* 17 15.7 26.6 0.009
   Parametria > 53 Gy* 9 51.8 37.7  
EORTC = European Organization for Research and Treatment of Cancer; GI = gastrointestinal; GU 
= genitourinary; QLQ-C30 = quality of life questionnaire for cancer patients 30; QLQ-CX24 = quality 
of life questionnaire cervical cancer module
*expressed as equivalent dose in 2-Gy fractions (EQD2) with α/β = 10
we also demonstrated an improved global health 
status and fewer chronic GI symptoms by reduc-
tion of acute toxicities with IMRT.16 Since most of 
the patients in our current analysis were treated 
with IMRT, we were unable to demonstrate such a 
benefit in terms of long-term QoL. Apart from the 
dose-volume-relationship found in both, acute and 
late toxicities, chronic toxicities may be consequen-
tial to acute damage, thus amelioration of the acute 
response to irradiation may be a useful approach to 
minimize late side effects.17 
Our analysis showed a significant impairment of 
sexual/vaginal functioning, significantly increased 
sexual worry, and a trend towards more chronic 
constipation in patients exceeding an EQD210 of 
53 Gy in the parametria. This was equally true for 
patients with SIB or sequential boost. The required 
dose to the parametria for adequate local tumour 
control has not been established and dose prescrip-
tions vary greatly among radiation oncologists.2,18 
In patients with traditional midline-shielding, 
parametrial boost resulted in a significantly higher 
incidence of radiation proctitis and enterocolitis 
when > 54 Gy were applied.19,20 and this technique 
has been described to substantially contribute to 
rectum, sigmoid and bladder doses.21 In the times 
of IMRT and SIB to the parametria, studies have 
shown, that local dose escalation can be achieved 
with a relevantly reduced incidence of acute tox-
icities.7,22 So far, no study has ever looked at per-
cutaneous parametrial dose escalation regarding 
QoL and chronic morbidity. Particularly, chronic 
vaginal morbidity after EBRT boost has not been 
the focus of research so far. The Vienna group has 
provided important evidence, that IGABT deliv-
ers superior outcome.3,23 and can reduce vaginal 
morbidity significantly, but sexual dysfunction 
remained a problem in patients treated within the 
EMBRACE trial as well.13,24 It is assumed that vagi-
nal toxicity may be further reduced with IGABT 
by decreasing dwell times in the ovoid/ring and 
increasing dwell times in tandem/needles.25,26  In 
this context it is important to state that the ongoing 
EMBRACE-2 trial limits percutaneous IMRT boost 
as SIB to involved lymph nodes and does not al-
low a parametrial IMRT boost.5 At our institution, 
MRI-guided IGABT with combined IBT/ICBT was 
recently implemented and we are currently plan-
ning a study with longitudinal QoL assessment in 
these patients. Certainly, it should be the ultimate 
goal to enable access to IGABT at all brachytherapy 
facilities. Nevertheless, at the moment, availability 
of IBT and MRI-guidance is low at most brachy-
therapy centers and EBRT boost remains a widely 
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used method for parametrial dose escalation. This 
underlines the importance of our investigation. 
While survival rates were generally adequate in 
our study and in line with previously published 
data from randomized controlled trials on RChT in 
patients with ACC, a comparison of our results to 
data on IGABT is quite challenging because our co-
hort consists of mostly advanced stage patients.27,28 
The RetroEMBRACE study, a multicenter retro-
spective observational study, found substantially 
better 5-year pelvic control and overall survival 
rates (84% vs. 73.2% and 65% vs. 53.2%), but their 
cohort contained much more stage I and far less 
stage IV patients than our study (16.8% vs. 2.4% 
and 3.1% vs. 31.3%) (23). A Dutch retrospective 
analysis on 46 patients treated with IGABT found 
a 3-year regional control rate of 86% and a 3-year 
overall survival rate of 65%.29  Similarly, Pötter et 
al. found pelvic control and overall survival to be 
91% and 68% after 3-years, respectively.3 The pa-
tient cohorts in these two studies were very simi-
lar to the collective of the RetroEMBRACE study. 
Therefore, our results, despite the large proportion 
of stage IV patients and the negligible amount of 
stage I patients, are not inferior in terms of overall 
survival and seem comparable with respect to local 
pelvic control. However, primary tumour control 
was remarkably high with 93% after 3 years in the 
Vienna series.3 Furthermore, an analysis from the 
RetroEMBRACE study comparing IGABT with 
IBT/ICBT to ICBT only showed the feasibility of lo-
cal dose escalation without an increase in dose to 
organs at risk as well as a 10% higher 3-year local 
control rate with IBT.30 These results clearly dem-
onstrate the advantage of MRI-based IGABT with 
combined IBT/ICBT for local dose escalation. 
Nevertheless, our analysis showed a statistically 
significant overall survival benefit from a parame-
trial boost and this was equally true for patients 
with SIB or sequential boost. Alongside with si-
multaneous ChT, parametrial boost was as an inde-
pendent prognostic factor for OS in the multivari-
ate analysis. Local control was also improved in 
patients with parametrial boost, but, probably due 
to the comparatively few events, this did not reach 
statistical significance. However, the survival ben-
efit was dependent on the applied dose. In particu-
lar, overall survival was statistically significantly 
prolonged in patients with a parametrial EQD210 > 
50 Gy, but a dose escalation beyond an EQD210 of 
53 Gy did not further improve survival. Thus, we 
believe IMRT with 25 x 1.8 Gy to the whole pelvic 
PTV including a SIB with 25 x 2.1 Gy to the para-
metria to be a feasible and overall efficient EBRT 
concept for centers without access to IGABT.
We acknowledge that our study is substantially 
limited by its retrospective nature, the compara-
tively small sample size and the conductance of 
multiple subgroup analyses, but we believe our 
results on parametrial dose and chronic morbidity 
to be of importance for all brachytherapy centers 
without access to MRI-guidance and IBT.
Primary RChT is an effective treatment for 
ACC, but long-term QoL of survivors is inferior 
compared to normative data. The degree of acute 
side effects of RChT correlates with the extent of 
chronic symptoms. For patients treated with EBRT 
boost and ICBT, we have shown a significant sur-
vival benefit from parametrial dose escalation as 
SIB or sequential boost, but exceeding an EQD210 
of 53 Gy with this technique does not further im-
prove survival and has a negative impact on QoL. 
Therefore, the conductance of a percutaneous par-
ametrial boost has to be seen very critically with 
respect to local tumour control and long-term QoL. 
MRI-guided IGABT with combined IBT/ICBT cer-
tainly is the gold standard for local dose escalation 
in ACC.
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